BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250731T062321EDT-2742i2Vn5i@132.216.98.100
DTSTAMP:20250731T102321Z
DESCRIPTION:Enzyme inhibition has proven to be a successful paradigm for ph
 armaceutical development\, however\, it has several limitations.  As an al
 ternative\, for the past 16 years\, my lab has focused on developing Prote
 olysis Targeting Chimera (PROTAC)\, a new ‘controlled proteolysis’ technol
 ogy that overcomes the limitations of the current inhibitor pharmacologica
 l paradigm. Based on an ‘Event-driven’ paradigm\, PROTACs offer a novel\, 
 catalytic mechanism to irreversibly inhibit protein function\, namely\, th
 e intracellular destruction of target proteins. This approach employs hete
 robifunctional molecules capable of recruiting target proteins to the cell
 ular quality control machinery\, thus leading to their degradation.   We h
 ave demonstrated the ability to degrade a wide variety of targets (kinases
 \, transcription factors\, epigenetic readers) with PROTACs at picomolar c
 oncentrations.  Moreover\, the PROTAC technology has been demonstrated wit
 h multiple E3 ubiquitin ligases\, included pVHL and cereblon.\n
DTSTART:20171017T170000Z
DTEND:20171017T183000Z
LOCATION:Rm 10\, Maass Chemistry Building\, CA\, QC\, Montreal\, H3A 0B8\, 
 801 rue Sherbrooke Ouest
SUMMARY:Chemical Society Seminar: Dr. Craig Crews - PROTAC-mediated Protein
  Degradation: The Chemical Equivalent of CRISPR
URL:/chemistry/channels/event/chemical-society-seminar
 -dr-craig-crews-protac-mediated-protein-degradation-chemical-equivalent-27
 5608
END:VEVENT
END:VCALENDAR